- Home
- RDHL vs PALI Comparison
RDHL vs PALI Comparison
Compare RDHL & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- PALI
- Stock Information
- Founded
- RDHL 2009
- PALI 1996
- Country
- RDHL Israel
- PALI United States
- Employees
- RDHL N/A
- PALI N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RDHL Health Care
- PALI Health Care
- Exchange
- RDHL Nasdaq
- PALI Nasdaq
- Market Cap
- RDHL 3.8M
- PALI 3.2M
- IPO Year
- RDHL N/A
- PALI N/A
- Fundamental
- Price
- RDHL $1.99
- PALI $0.70
- Analyst Decision
- RDHL
- PALI Strong Buy
- Analyst Count
- RDHL 0
- PALI 2
- Target Price
- RDHL N/A
- PALI $12.00
- AVG Volume (30 Days)
- RDHL 214.4K
- PALI 410.9K
- Earning Date
- RDHL 04-10-2025
- PALI 05-12-2025
- Dividend Yield
- RDHL N/A
- PALI N/A
- EPS Growth
- RDHL N/A
- PALI N/A
- EPS
- RDHL N/A
- PALI N/A
- Revenue
- RDHL $8,042,999.00
- PALI N/A
- Revenue This Year
- RDHL $381.91
- PALI N/A
- Revenue Next Year
- RDHL N/A
- PALI N/A
- P/E Ratio
- RDHL N/A
- PALI N/A
- Revenue Growth
- RDHL 23.17
- PALI N/A
- 52 Week Low
- RDHL $1.71
- PALI $0.60
- 52 Week High
- RDHL $20.28
- PALI $5.15
- Technical
- Relative Strength Index (RSI)
- RDHL 51.03
- PALI 44.12
- Support Level
- RDHL $1.82
- PALI $0.67
- Resistance Level
- RDHL $1.93
- PALI $0.86
- Average True Range (ATR)
- RDHL 0.08
- PALI 0.06
- MACD
- RDHL 0.04
- PALI -0.01
- Stochastic Oscillator
- RDHL 100.00
- PALI 22.24
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.